Global Systemic Lupus Erythematosus (SLE) Drugs Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030 from USD 2.3 billion in 2018. The market is driven by factors such as increasing prevalence of SLE, rising awareness about the disease and its treatment options, and technological advancements in drug development.
The global systemic lupus erythematosus drugs market is segmented on the basis of type into corticosteroids, NSAIDs, antinflammatory drugs (AIDs), DMARDs, antimalarials, BLy specific inhibitors or monoclonal antibodies (MAbS), immunosuppressive agents/immune modulators and anticoagulants; on the basis of application into intravenous (IV), subcutaneous (SC), oral (Oral) and topical; and on the basis of region into North America, Latin America Europe Asia Pacific Middle East & Africa).
Some Of The Growth Factors Of This Market:
- In addition, the introduction of novel therapies for SLE is also expected to fuel its growth in the near future as these therapies offer better efficacy and safety profiles than existing treatments for this disease.
- Furthermore, increasing awareness about lupus among physicians and patients will also drive its demand in coming years as it will help them identify symptoms early on and seek treatment accordingly before it becomes severe or chronic in nature which can lead to irreversible damage or death if left untreated for long periods of time.
Industry Growth Insights published a new data on “Systemic Lupus Erythematosus (SLE) Drugs Market”. The research report is titled “Systemic Lupus Erythematosus (SLE) Drugs Market research by Types (Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Anticoagulants), By Applications (Intravenous, Sub-Cutaneous, Oral, Topical), By Players/Companies Anthera Pharmaceuticals, GSK, ImmuPharma, Johnson & Johnson”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Lupus Erythematosus (SLE) Drugs Market Research Report
By Type
Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Anticoagulants
By Application
Intravenous, Sub-Cutaneous, Oral, Topical
By Companies
Anthera Pharmaceuticals, GSK, ImmuPharma, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Drugs Industry Outlook.svg)
Global Systemic Lupus Erythematosus (SLE) Drugs Market Report Segments:
The global Systemic Lupus Erythematosus (SLE) Drugs market is segmented on the basis of:
Types
Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Anticoagulants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intravenous, Sub-Cutaneous, Oral, Topical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Anthera Pharmaceuticals
- GSK
- ImmuPharma
- Johnson & Johnson
 Drugs Market Overview.svg)
Highlights of The Systemic Lupus Erythematosus (SLE) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Anti-Inflammatories
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Antimalarials
- BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
- Immunosuppressive Agents/Immune Modulators
- Anticoagulants
- By Application:
- Intravenous
- Sub-Cutaneous
- Oral
- Topical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Lupus Erythematosus (SLE) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic lupus erythematosus (SLE) drugs are medications used to treat the symptoms of SLE. These medications can help reduce inflammation and pain, improve blood flow, and protect the kidneys. Some common SLE drugs include hydroxychloroquine (Plaquenil), azathioprine (Azathioprine), cyclophosphamide (Cytoxan), and prednisone (Prednisone).
Some of the major companies in the systemic lupus erythematosus (sle) drugs market are Anthera Pharmaceuticals, GSK, ImmuPharma, Johnson & Johnson.
The systemic lupus erythematosus (sle) drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Systemic Lupus Erythematosus (SLE) Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Systemic Lupus Erythematosus (SLE) Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Systemic Lupus Erythematosus (SLE) Drugs Market - Supply Chain
4.5. Global Systemic Lupus Erythematosus (SLE) Drugs Market Forecast
4.5.1. Systemic Lupus Erythematosus (SLE) Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Systemic Lupus Erythematosus (SLE) Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Systemic Lupus Erythematosus (SLE) Drugs Market Absolute $ Opportunity
5. Global Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Type
5.3.1. Corticosteroids
5.3.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
5.3.3. Anti-Inflammatories
5.3.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
5.3.5. Antimalarials
5.3.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
5.3.7. Immunosuppressive Agents/Immune Modulators
5.3.8. Anticoagulants
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
6.3.1. Intravenous
6.3.2. Sub-Cutaneous
6.3.3. Oral
6.3.4. Topical
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Systemic Lupus Erythematosus (SLE) Drugs Demand Share Forecast, 2019-2026
9. North America Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
9.4.1. Intravenous
9.4.2. Sub-Cutaneous
9.4.3. Oral
9.4.4. Topical
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Type
9.7.1. Corticosteroids
9.7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
9.7.3. Anti-Inflammatories
9.7.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
9.7.5. Antimalarials
9.7.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
9.7.7. Immunosuppressive Agents/Immune Modulators
9.7.8. Anticoagulants
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Systemic Lupus Erythematosus (SLE) Drugs Demand Share Forecast, 2019-2026
10. Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
10.4.1. Intravenous
10.4.2. Sub-Cutaneous
10.4.3. Oral
10.4.4. Topical
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Type
10.7.1. Corticosteroids
10.7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
10.7.3. Anti-Inflammatories
10.7.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
10.7.5. Antimalarials
10.7.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
10.7.7. Immunosuppressive Agents/Immune Modulators
10.7.8. Anticoagulants
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Systemic Lupus Erythematosus (SLE) Drugs Demand Share Forecast, 2019-2026
11. Europe Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
11.4.1. Intravenous
11.4.2. Sub-Cutaneous
11.4.3. Oral
11.4.4. Topical
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Frecast by Type
11.7.1. Corticosteroids
11.7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
11.7.3. Anti-Inflammatories
11.7.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
11.7.5. Antimalarials
11.7.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
11.7.7. Immunosuppressive Agents/Immune Modulators
11.7.8. Anticoagulants
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Systemic Lupus Erythematosus (SLE) Drugs Demand Share, 2019-2026
12. Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
12.4.1. Intravenous
12.4.2. Sub-Cutaneous
12.4.3. Oral
12.4.4. Topical
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Type
12.7.1. Corticosteroids
12.7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
12.7.3. Anti-Inflammatories
12.7.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
12.7.5. Antimalarials
12.7.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
12.7.7. Immunosuppressive Agents/Immune Modulators
12.7.8. Anticoagulants
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Demand Share, 2019-2026
13. Middle East & Africa Systemic Lupus Erythematosus (SLE) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Application
13.4.1. Intravenous
13.4.2. Sub-Cutaneous
13.4.3. Oral
13.4.4. Topical
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Systemic Lupus Erythematosus (SLE) Drugs Market Size and Volume Forecast by Type
13.7.1. Corticosteroids
13.7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
13.7.3. Anti-Inflammatories
13.7.4. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
13.7.5. Antimalarials
13.7.6. BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
13.7.7. Immunosuppressive Agents/Immune Modulators
13.7.8. Anticoagulants
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Systemic Lupus Erythematosus (SLE) Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Systemic Lupus Erythematosus (SLE) Drugs Market: Market Share Analysis
14.2. Systemic Lupus Erythematosus (SLE) Drugs Distributors and Customers
14.3. Systemic Lupus Erythematosus (SLE) Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Anthera Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. ImmuPharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17.&n
